课题基金 / 基金详情

Development of anti-HCV therapy the regulation of NS5A function

Development of anti-HCV therapy the regulation of NS5A function
抗HCV疗法的发展NS5A功能的调节
批准号:
12557053
负责人:
ENOMOTO Nobuyuki
金额:
$7.49万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002

项目摘要

项目成果

ENOMOTO Nobuyuki的其他基金

相似基金

相关文献

中文摘要
翻译
丙型肝炎病毒(丙型肝炎病毒)亚基因组复制子在人肝癌细胞Huh-7中持续高效复制。为了将先前的结果推广到其他分离的丙型肝炎病毒克隆,我们从黑猩猩感染的克隆之一HC-J4中构建了另一个丙型肝炎病毒复制子。丙型肝炎病毒复制子RpJ4由丙型肝炎病毒5‘-非编码区、新霉素磷酸转移酶基因、脑心肌炎病毒IRES、非结构区、NS3到NS5B和丙型肝炎病毒3’-非编码区组成。已知的丙型肝炎病毒-Con1复制子所需的适应性突变被引入到RpJ4复制子a.(氨基酸数量根据HC-J4)2197丝氨酸到脯氨酸,aa.2201丝氨酸缺失,aa.2204丝氨酸到异亮氨酸(RpJ4-S2I97P,RpJ4-S22001del,和RpJ4-S2204I)。在干扰素敏感性决定区(ISDR)引入6个氨基酸突变,构建了RpJ4/ISDR突变体和RpJ4-S2201del/ISDR突变体。将复制子RNA导入Huh-7细胞,经G418筛选获得稳定表达复制子的细胞系。RpJ4和RpJ4/ISDR突变株在转染初代Huh-7细胞后未产生G418抗性克隆。相反,RpJ4-S2197P、RpJ4-S2204I、RpJ4-S2201del和RpJ4-S2201del/ISDR突变体可以有效地转导G418抗性细胞,其中RpJ4-S2201del/ISDR突变体的转导效率最高。总之,在ISDR的上游区域引入适应性突变后,来自HC-J4的丙型肝炎病毒复制子可以有效地复制。此外,在ISDR中额外引入突变进一步增强了其复制能力。这些发现表明,NS5A结构域的遗传结构在丙型肝炎病毒1b复制中起关键作用。
英文摘要
Hepatitis C virus (HCV) subgenomic replicon has been reported to replicate efficiently and continuously in human hepatoma Huh-7 cells. To extend the previous results to other isolated HCV clones, we have constructed another HCV replicon from HC-J4, one of the chimpanzee-infectious clones. An HCV-replicon derived from HC-J4 (RpJ4) consists of HCV-5'-UTR, neomycin phosphotransferase gene, the encephalomyocarditis virus IRES, HCV-nonstructural region, NS3 to NS5B, and HCV-3'-UTR. The adaptive mutations known to be required for HCV-Conl replicon were introduced in RpJ4 replicon, aa.(amino acids number according to HC-J4) 2197 serine to proline, deletion of serine at aa.2201, and aa.2204 serine to isoleucine (RpJ4-S2I97P, RpJ4-S22001del, and RpJ4-S2204I). RpJ4/ISDRmutant and RpJ4-S2201del/ISDRmutant were also constructed by introducing six amino acid mutations into the interferon sensitivity determining region (ISDR). Replicon RNA was transfected into Huh-7 cells, and stable replicon-expressing cell lines were established by G418 selection. After transfection to naive Huh-7 cells, RpJ4 and RpJ4/ISDRmutants did not produce any G418-resistant colonies. In contrast, G418-resistant cells were transduced efficiently by RpJ4-S2197P, RpJ4-S2204I, RpJ4-S2201del and RpJ4-S2201del/ISDRmutants, with the RpJ4-S2201del/ISDRmutant being most efficient. In conclusion, The HCV replicon derived from HC-J4 can replicate efficiently following the introduction of adaptive mutations into the upstream region of ISDR. Moreover, additional introduction of mutations into ISDR further enhances its replication. These findings demonstrate that the genetic structure of the NS5A domain is critical in HCV-1b replications.
期刊论文(24)
专著(0)
科研奖励(0)
会议论文
Nagayama K, Enomoto N, Izumi N, Kurosaki M, Miyasaka Y, Watanabe H, Itakura J, Chen C-H, Tazawa J, Ikeda T, Marumo F, Sato C.: "Sequences in the NS5A Protein of Genotype 1b Hepatitis C Virus and the Serum ALT Response to Interferon Therapy in Japanese Pat
Nagayama K、Enomoto N、Izumi N、Kurosaki M、Miyasaka Y、Watanabe H、Itakura J、Chen C-H、Tazawa J、Ikeda T、Marumo F、Sato C.:“基因型 1b 丙型肝炎病毒的 NS5A 蛋白序列和
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Watanabe, H, Enomoto, N, et al.: "Number and Position of Mutations in the Interferon Sensitivity-Determining Region of the Gene for Nonstructural Protein 5A Correlates with Interferon Efficacy in Hepatitis C Virus Genotype 1b Infection"J Infect Dis. 183.
Watanabe, H, Enomoto, N 等人:“非结构蛋白 5A 基因干扰素敏感性决定区域中突变的数量和位置与丙型肝炎病毒基因型 1b 感染中的干扰素功效相关”J Infect Dis。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Nagayama, K, Enomoto, N, et al.: "Overexpression of interferon gamma-inducible protein 10 in the liver of patients with type I autoimmune hepatitis identified by suppression subtractive hybridization"Am J Gastroenterol. 96. 2211-2217 (2001)
Nagayama, K, Enomoto, N 等人:“通过抑制消减杂交鉴定出 I 型自身免疫性肝炎患者肝脏中干扰素 γ 诱导蛋白 10 的过度表达”Am J Gastroenterol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Itakura, J, Enomoto, N, et al.: "CD81 Nucleotide Mutation in Hepatocellular Carcinoma and No CD81 Polymorphism in Patients with Various Stages of Hepatitis C Virus Infection"J Med Virol. 63. 22-28 (2001)
Itakura, J, Enomoto, N 等人:“肝细胞癌中的 CD81 核苷酸突变和丙型肝炎病毒感染各个阶段的患者中无 CD81 多态性”J Med Virol。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
共 12 条
    Next-generation sequence of cancer-related genes in digestive organ cancers using clinical samples
    • 批准号:
      26670380
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.33万
    • 财政年份:
      2014
    • 负责人:
      ENOMOTO Nobuyuki
    • 依托单位:
    Clarifying the pathogenesis of chronic hepatitis C through comprehensive genetic analyses of the virus and host using next-generation sequencer
    • 批准号:
      23390195
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.4万
    • 财政年份:
      2011
    • 负责人:
      ENOMOTO Nobuyuki
    • 依托单位:
    Analysis ofchronic viral hepaptis by the large-scale next generation sequeincing
    • 批准号:
      21659186
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.11万
    • 财政年份:
      2009
    • 负责人:
      ENOMOTO Nobuyuki
    • 依托单位:
    Comprehensive analysis of chronic hepatitis C by large-scale viral genome wide analysis
    • 批准号:
      20390206
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $11.98万
    • 财政年份:
      2008
    • 负责人:
      ENOMOTO Nobuyuki
    • 依托单位:
    国内基金
    海外基金
    三种凤尾蕨属植物中吡咯生物碱及其抗菌和抗HCV病毒功能研究
    • 批准号:
      82360689
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      32.00万元
    • 批准年份:
      2023
    • 负责人:
      邹娟
    • 依托单位:
    KIR/HLAI基因遗传变异及HCV逃逸突变与感染免疫应答相关性的分子流行病学及机制研究
    • 批准号:
      82273691
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      岳明
    • 依托单位:
    基于“逆向免疫学”理论筛选具有交叉保护作用的抗HCV抗原表位的研究
    • 批准号:
      --
    • 项目类别:
      面上项目
    • 资助金额:
      52万元
    • 批准年份:
      2022
    • 负责人:
      边中启
    • 依托单位:
    云南省HCV感染人群C19orf66基因遗传易感性分析及其机制研究
    • 批准号:
      32160148
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      34万元
    • 批准年份:
      2021
    • 负责人:
      张阿梅
    • 依托单位: